Melanoma TrialFinder

For professionals

Find a trial

20 trials in 46 locations

MoleGazer: A Feasibility Study for Early Detection of Melanoma

Melanoma (skin cancer) frequently develops from existing moles on the skin. Current practice relies on expert dermatologists being able to successfully identify new/changing moles in individuals with multiple moles. Total body photography (TBP-high-quality images of the entire skin) can track and monitor moles over time to detect melanoma.However, TBP is currently used as a visual guide when diagnosing melanoma, requiring visual inspection of each mole sequentially. This process is challenging, time-consuming and inefficient. Artificial [...]

Locations: Churchill Hospital (PI: Rubeta Matin)

NAVIGATE: A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. [...]

Locations: Beatson West of Scotland Cancer Centre (PI: Patricia Roxburgh), University College London Hospitals NHS Foundation Trust (UCLH) (PI: Martin Forster),

The SCOPE Study: A Phase 2, Multicentre, Open-Label Study of SCIB1 in Patients with Advanced Unresectable Melanoma Receiving Either Nivolumab with Ipilimumab or Pembrolizumab

The purpose of this study is to find out if a new treatment cancer vaccine called SCIB1 can be used safely when added to either nivolumab (Opdivo) with ipilimumab (Yervoy) or pembrolizumab (Keytruda), standard treatments approved for patients with advanced melanoma (skin cancer).The study will also look to see if SCIB1 can increase the likelihood that melanoma patients will respond to either nivolumab with ipilimumab or pembrolizumab, and also if SCIB1 can help to [...]

Locations: Royal Preston Hospital (PI: Kellati Prasad), Somerset NHS Foundation Trust (PI: Gihan Ratnayake), Churchill Hospital, Oxford University NHS Trust (PI: Miranda Payne), Mount Vernon Hospital, East and North Hertfordshire NHS Trust (PI: Heather Shaw), Nottingham University Hospitals NHS Trust (PI: Poulam Patel), Weston Park Hospital (PI: Sarah Danson), Velindre University NHS Trust (PI: Satish Kumar)

ARTISTRY-6: A Phase 2, Open-label, Multicentre, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy

This study observes the anti-tumour activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy [...]

Locations: Oxford University Hospitals NHS Foundation Trust (PI: Prof. Mark Middleton), THE ROYAL MARSDEN HOSPITAL (LONDON) (PI: James Larkin), The Christie NHS Foundation Trust (PI: Avinash Gupta)

TebeMRD: A Phase II Non-Randomized, Open-label, Multi-centre Study of the Safety and Efficacy of Tebentafusp in Melanoma With Molecular Relapsed Disease

Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma [...]

Locations: Churchill Hospital (PI: Mark Middleton), Mount Vernon Cancer Centre (PI: Paul Nathan)

MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition. [...]

Locations: Addenbrookes Hospital (PI: Pippa Corrie), The Royal Marsden Hospital (LONDON) (PI: James Larkin), Mount Vernom Hospital (PI: Paul Nathan), The Royal Marsden Hospital (SURREY) (PI: James Larkin)

MITRE: An Observational Study to Evaluate the Microbiome as a Biomarker of Efficacy and Toxicity in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy

This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer. [...]

Locations: Weston Park Hospital (PI: Sarah Danson), Velindre Cancer Centre (PI: Ricky Frazer), Bristol Haematology and Oncology Centre (PI: Helen Winter), Norfolk and Norwich University Hospitals (PI: Jenny Nobes), Somerset NHS Foundation Trust (PI: Clare Barlow), Royal Cornwall Hospital (PI: Toby Talbot), Western General Hospital (PI: Ewan Brown), Addenbrookes, Cambridge University Hospitals NHS Trust (PI: Pippa Corrie), Royal United Hospital Bath (PI: Tania Tillett), University Hospital Southampton (PI: Matthew Wheater), Leicester Royal Infirmary (PI: Guy Faust), Royal Bournemouth Hospital (PI: Tom Geldart)

THETIS (ATX-ME-001): An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Metastatic or Recurrent Melanoma

This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma. [...]

Locations: University College London Hospital (UCLH) (PI: Heather Shaw), Cambridge University Hospitals NHS Foundation Trust (PI: Brent O'Carrigan), University Hospital Southampton (PI: Ioannis Karydis), The Royal Marsden Hospital (LONDON) (PI: Samra Turajlic), Guys and St Thomas's NHS Foundation Trust (PI: Rebecca Kristeleit), Freeman Hospital (PI: Ruth Plummer), The Christie NHS Foundation Trust (PI: Fiona Thistlethwaite)

IGNYTE: An Open-Label, Multicentre, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumours, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.THIS TRIAL IS CURRENTLY ONTO PHASE 2. [...]

Locations: The Clatterbridge Cancer Centre NHS Foundation Trust (PI: Joseph Sacco), The Royal Marsden Hospital (LONDON) (PI: Kevin Harrington), St James's University Hospital (PI: Adel Samson), University Hospital Southampton (PI: Ioannis Karydis), Churchill Hospital (PI: Mark Middleton), Beatson West of Scotland Cancer Center (PI: Patricia Roxburgh)

DETECTION: Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION

Having surgery to remove the melanoma will cure the majority of patients with early stage disease. However, a small percentage of these patients will go on to develop further disease, which may spread to other places in their body.Currently, patients who have been cured of melanoma will have appointments in clinic to check that further disease has not developed or returned and some may also receive regular scans.The trial team has developed a blood [...]

Locations: Churchill Hospital (PI: Miranda Payne), Nottingham City Hospital (PI: Hester Franks), Addenbrookes Hospital (PI: Brent O'Carrigan), The Christie NHS Foundation Trust (PI: Paul Lorigan), The Beatson West of Scotland Cancer Centre (PI: Ashita Waterston)

DANTE: Duration of Anti-PD1 therapy for melanoma

This trial aims to determine whether anti-PD1 monotherapy to treat advanced melanoma can be stopped after 1 year, rather than the current standard practice (i.e. continuing to treat until disease progression/unacceptable toxicity, or for at least 2 years), and achieve and maintain as good an outcome (in terms of the cancer coming back). The hypothesis is that continuing treatment beyond 1 year is unnecessary, as there is no biological evidence that justifies continuous therapy; [...]

Locations: This trial is no longer recruiting new patients

INITIUM STUDY: Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma

This is now a single arm study amendment to investigate the efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment of adult patients with histologically confirmed unresectable metastatic melanoma. UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in metastatic melanoma. [...]

Locations: The Christie NHS Foundation Trust (PI: Paul Lorigan)

PECan: Measurement of PDL1 Expression in Cancer to Monitor Treatment Response.

Measurement of PDL1 expression in cancer to monitor treatment response.A prospective single centre non-randomised exploratory observational study.To determine the baseline level and variability within and between patients and tumour types of PDL1 expression in melanoma and non-small cell lung cancer in immunotherapy naïve patients using [99mTc]-anti-PDL1 SPECT and immunohistochemistry. [...]

Locations: Guy's and St Thomas' NHS Trust (PI: Professor Gary Cook)

MISST: Melanoma Immunomodulation and Immune Responses of the Skin Study: A Translational Science Research Protocol

In this study we aim to investigate the nature of immune responses in human skin and in melanoma and to utilise these insights in order to explore potential novel treatment and clinical management avenues to benefit patients. T cells, B cells and other inflammatory and cytotoxic cells, such as monocytes and macrophages, found in the circulation and the tumour lesions of patients with melanoma will be investigated and compared with those from healthy volunteers.We [...]

Locations: Guy's and St Thomas' NHS Trust (PI: Katie Lacy)

MelMarT-II: Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in [...]

Locations: The Royal Marsden NHS Foundation Trust (PI: Myles Smith), Cambridge University Hospitals NHS Trust (PI: Amit Roshan and Amer Durrani), Nottingham University Hospitals NHS Trust (PI: Jonathan Pollock), Royal Cornwall Hospital (PI: Polly King), Queen Victoria Hospital NHS Foundation Trust (PI: Siva Kumar), Hull University Teaching Hospitals NHS Trust (PI: Paolo Matteucci), Oxford University Hospitals NHS Foundation Trust (PI: Oliver Cassell), Norfolk and Norwich University Hospital (PI: Prof Marc Moncrieff), Guys and St Thomas' NHS Foundation Trust (PI: Jenny Geh), North Bristol NHS Trust (PI: Ewan Wilson), The Leeds Teaching Hospitals NHS Trust (PI: Howard Peach), St George's University Hospitals NHS Foundation Trust (PI: Joy Odili), Royal Free London NHS Foundation Trust (PI: Stephen Hamilton), University Hospitals Birmingham NHS Foundation Trust (PI: Dr Agustin Martin-Clavijo), Mid and South Essex NHS Trust (PI: Professor Peter Dziewulski), St Helen's & Knowsley Hospitals Trust (PI: Prof Rowan Pritchard Jones), South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital (PI: Oliver Bassett)

BNT111-01: Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

This is an open-label, randomised, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-PD-1-refractory/relapsed patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent calibrator arms. Patients in single agent calibrator arms, who experience disease progression under single agent treatment, may be offered addition of the other compound to the ongoing treatment after re-consent. [...]

Locations: Royal Cornwall Hospital (PI: Toby Talbot), The Christie NHS Foundation Trust (PI: Paul Lorigan)

TEBENTAFUSP: Tebentafusp Managed Access Program for Metastatic Uveal Melanoma

Uveal melanoma (UM) is a rare and highly malignant neoplasm affecting the vascular layers of the eye (iris, ciliary body, or choroid). Once patients develop metastases, primarily to the liver, the prognosis is poor with a median survival of less than 12 months. There are no effective treatments for metastatic UM that extend survival, and there is no proven standard of care. Enrollment in clinical trials is the treatment option recommended by the UK [...]

Locations: Norfolk and Norwich University Hospital (PI: Jenny Nobes), The Royal Marsden (LONDON) (PI: Andrew Furness), Belfast City Hospital (PI: Judith Carser), Bristol Haematology and Oncology Centre (PI: Hannah Taylor), Royal Preston Hospital (PI: Kellati Prasad), Poole Hospital (PI: Rachel Plant), Cheltenham General Hospital (PI: David Farrugia), William Harvey Hospital (PI: Rosemeen Parkar), Castle Hill Hospital (PI: Dulani Ranataunge), East and North Hertfordshire NHS Trust (PI: Heather Shaw), Nottingham City Hospital (PI: Ankit Rao), University Hospital Birmingham (PI: Leila Khoja), Musgrove Park Hospital (PI: Clare Barlow), The Beatson West of Scotland Cancer Centre (PI: Yun Yi Tan), The Christie NHS Foundation Trust (PI: Paul Lorigan), Royal Cornwall Hospital (PI: Toby Talbot), The Clatterbridge Cancer Centre - LIVERPOOL (PI: Joseph Sacco), The Freeman Hospital (PI: Ruth Plummer)

IMP-MEL: Testing IMM60 in combination with pembrolizumab in melanoma and non-small cell lung cancer

The trial is a first-in-human study called the IMP-MEL trial and is sponsored by the University of Oxford; the information we get from this trial may help us to improve the future treatment of patients with melanoma and non-small cell lung cancer. The experimental drug, called IMM60, has not been given to patients before.This trial will aim to:• Establish the safe dose of IMM60• Establish that the safe dose of IMM60 can be safely [...]

Locations: John Radcliffe Hospital (PI: Prof. Mark Middleton), Hammersmith Hospital (PI: David Pinato)

OOB: The Liverpool Ocular Oncology Biobank

The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. By doing this, the biobank can build a valuable collection that will be used by research groups across the world to address key basic and clinical research questions necessary to improve the healthcare of future [...]

Locations: The Liverpool Ocular Oncology Centre (PI: Dr Helen Kalirai (Biobank Custodian))

MAAM Study: The use of Microwave Ablation in the treatment of advanced melanoma with cutaneous metastases. An observational study using Emblation's microwave based treatment system SwiftTM

This is a pilot study to establish if MWA can successfully treat metastatic melanoma deposits using the Swift device manufactured by Emblation. As a control group, they will also test whether MWA can treat other skin lesions where standard surgical management is not recommended (including other skin cancer metastases, viral warts). The hypothesis is that precise directed delivery of microwave energy onto a melanoma deposit will lead to its destruction. In this biomarker [...]

Locations: University Hospital Southampton (PI: Danny O'Driscoll (study coordinator))